CORCORAN B, BLACK A, ANDERSON H, DUKES MAC EVAN J, FRENCH A

Investigation of mitral valve morphology in dogs with mitral valve endocardiosis using scanning electron microscopy. In: Proceedings of the 12th European College of Veterinary Internal Medicine/European Society of Veterinary Internal Medicine Congress. Munich, Germany, 19-21 September, 2002, 178.

43. CORCORAN BM, BLACK A, ANDERSON H, MCEWAN JD, FRENCH A, SMITH P et al. Identification of surface morphologic changes in the mitral valve leaflets and chordae tendineae of dogs with myxomatous degeneration. Am J Vet Res, 2004, 65 (2), 198-206.

44. DARKE PG. Valvular incompetence in Cavalier King Charles Spaniels. Vet Rec, 1987, 120 (15), 365-6.

45. DEMANY JM. Les affections mitrales chez le chien et leur traitement chirurgical : bilan et perspectives ; application au traitement de la sténose mitrale sous circulation extra-corporelle.

Thèse Med. Vet., Alfort, 2005, 148p.

46. DETWEILER DK. Wesen und Häufigkeit on Herzkrankheiten beim Hund. Zbld Vet Med, 1962, 9 317-56.

47. DOIGUCHI O, TAKAHASHI T. Examination of quantitative analysis and measurement of the regurgitation rate in mitral valve regurgitation by the "proximal isovelocity surface area"

method. J Vet Med Sci, 2000, 62 (1), 109-12.

48. DROOGMANS S, FRANKEN PR, GARBAR C, WEYTJENS C, COSYNS B, LAHOUTTE T et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology.

Eur Heart J, 2007, 28 (17), 2156-62.

49. ENRIQUEZ-SARANO M, AVIERINOS JF, MESSIKA-ZEITOUN D, DETAINT D, CAPPS M, NKOMO V et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med, 2005, 352 (9), 875-83.

50. ETTINGER SJ, BENITZ AM, ERICSSON GF, CIFELLI S, JERNIGAN AD, LONGHOFER SL et al. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. J Am Vet Med Assoc, 1998, 213 (11), 1573-7.

51. FALK T, JONSSON L, OLSEN LH, PEDERSEN HD. Arteriosclerotic changes in the myocardium, lung, and kidney in dogs with chronic congestive heart failure and myxomatous mitral valve disease. Cardiovasc Pathol, 2006, 15 (4), 185-93.

52. FUENTES VL. Use of pimobendan in the management of heart failure. Vet Clin North Am Small Anim Pract, 2004, 34 (5), 1145-55.

53. FUJII Y, ORITO K, MUTO M, WAKAO Y. Modulation of the tissue renin-angiotensin-aldosterone system in dogs with chronic mild regurgitation through the mitral valve. Am J Vet Res, 2007, 68 (10), 1045-50.

54. GAASCH WH, JOHN RM, AURIGEMMA GP. Managing asymptomatic patients with chronic mitral regurgitation. Chest, 1995, 108 (3), 842-7.

55. GOUNI V, SERRES F, POUCHELON JL, TISSIER R, LEFEBVRE HP, NICOLLE AP et al. Quantification of mitral valve regurgitation in dogs with degenerative mitral valve disease by use of the proximal isovelocity surface area method. J Am Vet Med Assoc, 2007, 231 (3), 399-406.

56. GRIFFITHS LG. Surgery for cardiac disease in small animals: current techniques. Vet Clin North Am Small Anim Pract, 2010, 40 (4), 605-22.

57. GRIFFITHS LG, ORTON EC, BOON JA. Evaluation of techniques and outcomes of mitral valve repair in dogs. J Am Vet Med Assoc, 2004, 224 (12), 1941-5.

58. GRIGIONI F, ENRIQUEZ-SARANO M, ZEHR KJ, BAILEY KR, TAJIK AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation, 2001, 103 (13), 1759-64.

59. GUSTAFSSON BI, HAUSO O, DROZDOV I, KIDD M, MODLIN IM. Carcinoid heart disease. Int J Cardiol, 2008, 129 (3), 318-24.

60. GUSTAFSSON BI, TOMMERAS K, NORDRUM I, LOENNECHEN JP, BRUNSVIK A, SOLLIGARD E et al. Long-term serotonin administration induces heart valve disease in rats.

Circulation, 2005, 111 (12), 1517-22.

61. HADIAN M, CORCORAN BM, BRADSHAW JP. Molecular changes in fibrillar collagen in myxomatous mitral valve disease. Cardiovasc Pathol, 2010, 19 (5), 141-8.

62. HÄGGSTRÖM J, KVART C, HANSSON K. Heart sounds and murmurs: changes related to severity of chronic valvular disease in the Cavalier King Charles Spaniel. J Vet Intern Med, 1995, 9 (2), 75-85.

64. HÄGGSTRÖM J, HOGLUND K, BORGARELLI M. An update on treatment and prognostic indicators in canine myxomatous mitral valve disease. J Small Anim Pract, 2009, 50 Suppl 1 25-33.

65. HÄGGSTRÖM J, HANSSON K, KVART C, SWENSON L. Chronic valvular disease in the Cavalier King Charles Spaniel in Sweden. Vet Rec, 1992, 131 (24), 549-53.

66. HÄGGSTRÖM J, HAMLIN RL, HANSSON K, KVART C. Heart rate variability in relation to severity of mitral regurgitation in Cavalier King Charles spaniels. J Small Anim Pract, 1996, 37 (2), 69-75.

67. HÄGGSTRÖM J, HANSSON K, KARLBERG BE, KVART C, OLSSON K. Plasma concentration of atrial natriuretic peptide in relation to severity of mitral regurgitation in Cavalier King Charles Spaniels. Am J Vet Res, 1994, 55 (5), 698-703.

68. HÄGGSTRÖM J, HANSSON K, KVART C, KARLBERG BE, VUOLTEENAHO O, OLSSON K. Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs. Am J Vet Res, 1997, 58 (1), 77-82.

69. HÄGGSTRÖM J, HANSSON K, KVART C, PEDERSEN HD, VUOLTEENAHO O, OLSSON K. Relationship between different natriuretic peptides and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous valve disease. J Vet Cardiol, 2000, 2 (1), 7-16.

70. HÄGGSTRÖM J, BOSWOOD A, O'GRADY M, JONS O, SMITH S, SWIFT S et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med, 2008, 22 (5), 1124-35.

71. HAMLIN RL, NAKAYAMA T. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. J Vet Intern Med, 1998, 12 (2), 93-5.

72. HAMLIN RL, BENITZ AM, ERICSSON GF, CIFELLI S, DAURIO CP. Effects of enalapril on exercise tolerance and longevity in dogs with heart failure produced by iatrogenic mitral regurgitation. J Vet Intern Med, 1996, 10 (2), 85-7.

73. HELMCKE F, NANDA NC, HSIUNG MC, SOTO B, ADEY CK, GOYAL RG et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation, 1987, 75 (1), 175-83.

74. ISHIKAWA T, TANAKA R, SUZUKI S, MIYAISHI Y, AKAGI H, IINO Y et al. The effect of angiotensin-converting enzyme inhibitors of left atrial pressure in dogs with mitral valve regurgitation. J Vet Intern Med, 2010, 24 (2), 342-7.

75. IUNG B, GOHLKE-BARWOLF C, TORNOS P, TRIBOUILLOY C, HALL R, BUTCHART E et al. Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J, 2002, 23 (16), 1253-66.

76. JEUNESSE E, WOEHRLE F, SCHNEIDER M, LEFEBVRE HP. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs. J Vet Cardiol, 2007, 9 (2), 63-8.

77. JOHNSON L, BOON J, ORTON EC. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med, 1999, 13 (5), 440-7.

78. JONSSON L. Coronary arterial lesions and myocardial infarcts in the dog. A pathologic and microangiographic study. Acta Vet Scand Suppl, 1972, 38 1-80.

79. KAMOHARA K, BANBURY M, CALABRO A, POPOVIC ZB, DARR A, OOTAKI Y et al. A novel technique for functional mitral regurgitation therapy: mitral annular remodeling. Heart Surg Forum, 2006, 9 (6), E888-92.